Nordicus Partners Corporation /
Orocidin
Nordicus Partners Corporation takes full ownership of Orocidin A/S
What happened
Nordicus Partners Corporation acquired 5.34% of Orocidin A/S on Nov. 12, 2024, making the clinical-stage biopharmaceutical company a wholly owned subsidiary. The transaction exchanged 200,000 restricted shares of Nordicus common stock for the shares.
Orocidin is a Denmark-based biopharmaceutical company focused on treatments for aggressive periodontitis.
The source
Everything on this page comes from the source below.
Nordicus Partners Corporation takes full ownership of Orocidin A/S
This document is the source for the companies, stage and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly